𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients

✍ Scribed by Eugene R. Schiff; Ching-Lung Lai; Stefanos Hadziyannis; Peter Neuhaus; Norah Terrault; Massimo Colombo; Hans L. Tillmann; Didier Samuel; Stefan Zeuzem; Leslie Lilly; Maria Rendina; Jean-Pierre Villeneuve; Nicole Lama; Craig James; Michael S. Wulfsohn; Hamid Namini; Christopher Westland; Shelly Xiong; Gavin S. Choy; Sally Van Doren; John Fry; Carol L. Brosgart

Book ID
118686869
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
137 KB
Volume
38
Category
Article
ISSN
0270-9139

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adefovir dipivoxil for wait-listed and p
Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results
✍ Eugene Schiff; Ching-Lung Lai; Stephanos Hadziyannis; Peter Neuhaus; Norah Terra 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

Wait-listed (n ϭ 226) or post-liver transplantation (n ϭ 241) chronic hepatitis B (CHB) patients with lamivudine-resistant hepatitis B virus (HBV) were treated with adefovir dipivoxil for a median of 39 and 99 weeks, respectively. Among wait-listed patients, serum HBV DNA levels became undetectable

Liver transplantation for chronic hepati
Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine
✍ Chung Mau Lo; Chi Leung Liu; George K. Lau; See Ching Chan; Irene O. Ng; Sheung 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

Lamivudine treatment in patients with chronic hepatitis B virus (HBV) infection may improve clinical state and suppress viral replication before liver transplantation. Emergence of lamivudine-resistant YMDD mutant is common. We report the results of liver transplantation in 16 patients with pretrans